Chemed/$CHE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Chemed

Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.

Ticker

$CHE

Primary listing

NYSE

Industry

Health Care Providers & Services

Employees

15,695

ISIN

US16359R1032

Chemed Metrics

BasicAdvanced
$6.9B
23.05
$20.53
0.59
$2.00
0.42%

What the Analysts think about Chemed

Analyst ratings (Buy, Hold, Sell) for Chemed stock.

Bulls say / Bears say

Chemed Corporation reported a 7.4% increase in revenue for Q3 2024, reaching $606.2 million, indicating strong operational performance. (Defense World)
The company declared a 25% increase in its quarterly dividend to $0.50 per share in August 2024, reflecting confidence in its financial health and commitment to shareholder returns. (CSIMarket)
VITAS Healthcare, a subsidiary of Chemed, expanded its operations by acquiring Covenant Care's hospice services in Florida and Alabama for $85 million in March 2024, enhancing its market presence. (CSIMarket)
Roto-Rooter, Chemed's plumbing and drain cleaning segment, reported a 6.9% decrease in revenue to $214.8 million in Q3 2024, indicating challenges in this business line. (Defense World)
The company's revenue growth of 7.23% in Q3 2023 was slightly below the Healthcare Facilities sector average of 7.58%, suggesting potential competitive pressures. (CSIMarket)
An insider sale of 1,326 shares by Executive Vice President Lee Spencer S on March 3, 2025, might raise concerns about internal perspectives on the company's valuation. (Financial Modeling Prep)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.

Chemed Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Chemed Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CHE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs